Abstract
Subsets of human natural killer (NK) cells were identified that differed in the capacity to be activated by interferon (IFN) or the IFN-inducer, polyriboinosinic:polyribocytidylic acid [poly(I):poly(C)]. These subsets, which represented effectors of both spontaneous and antibody-dependent cellular cytotoxicity, were physically separable on the basis of cell buoyant density changes induced by exposure of lymphocytes to hyperosmolar Ficoll-Hypaque solutions or by centrifugation of lymphocytes through hyperosmolar (350 mOs/kg) Percoll gradients. Hyperosmolar conditions per se altered neither cell viability, NK cell cytolytic activity, nor the capacity of NK cells in unseparated lymphocyte preparations to be activated by IFN. IFN-unresponsive NK cells, separated by centrifugation through a 350 mOs/kg Percoll layer of 1.069-1.070 g/cm3 specific density, constituted 20 +/- 4% of all active NK cells identified at the single cell level and, per active NK cell, killed comparably to unstimulated IFN-responsive NK cells in 51Cr release assays. Thus, the IFN-unresponsive phenotype was probably not attributable to NK cells that were in an activated state prior to IFN treatment. Surface marker analysis of active NK cells at the single cell l...Continue Reading
References
Apr 19, 1979·Nature·H SchellekensL Stitz
Sep 19, 1979·The Journal of Experimental Medicine·V KumarM Bennett
Oct 1, 1979·Cellular Immunology·M J DrollerP Perlmann
Jun 1, 1985·The Journal of Clinical Investigation·B S EdwardsE C Borden
Sep 15, 1972·Nature·I GresserD Brouty-Boyé
Jan 1, 1980·Scandinavian Journal of Immunology·J R OrtaldoR B Herberman
Feb 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·L M ReidB R Bloom
Mar 1, 1981·The Journal of Experimental Medicine·T TimonenR B Herberman
Sep 1, 1981·The Journal of Experimental Medicine·N MinatoB R Bloom
Sep 1, 1981·Scandinavian Journal of Immunology·M UllbergM Jondal
May 1, 1982·Cellular Immunology·G MasucciE Klein
Dec 15, 1982·International Journal of Cancer. Journal International Du Cancer·F BelardelliM T Maunoury
Oct 1, 1982·Journal of Clinical Immunology·J C Roder, H F Pross
Jan 13, 1983·Nature·T HercendJ Ritz
Jan 1, 1982·Cancer Immunology, Immunotherapy : CII·B S EdwardsK Smith-Zaremba
Mar 1, 1981·The Journal of Experimental Medicine·M Ullberg, M Jondal
Aug 1, 1981·The Journal of Experimental Medicine·J A LustM Bennett
Mar 1, 1981·Transplantation Proceedings·R C BurtonH J Winn
Jan 1, 1981·Journal of Clinical Immunology·H F ProssM S Patterson